How long knee-shot relief lasts

A study average cannot predict your exact relief

Many studies don’t follow people beyond a few months. After the last check, the study can’t say what happened later.

A result at six months describes the group on that date. It doesn’t mean every person changed at six months.

Some people get shorter relief, while others feel better longer. An average doesn’t show each person’s result.

Use that number as a rough guide for planning. Keep your own notes between visits because your result may differ.

Salt-water shots can also seem to ease soreness

People given salt water in studies sometimes reported less soreness. Symptoms can change with time, attention, and normal good or bad days.

Because soreness rises and falls, your memory before and after one shot can mislead you. Feeling better is real, but memory alone can’t show what caused it.

Reviews of medical studies combine results from several studies. Two reviews can disagree when they include different people, products, or follow-up times.

You don’t need to sort through those differences alone. Ask what amount and length of relief would be realistic for your knee.

A daily task shows whether relief lasts

Choose one normal task to watch, such as rising from a chair. Note how your knee feels before care and afterward.

Don’t judge the result from one good morning. Look for less soreness during your usual week.

Keep activity gentle while you watch for a steady change. Stop and seek advice if heat, swelling, or sharp soreness quickly rises.

Take your notes when you have an exam. QC Kinetix offers natural pain treatments that use blood its medical providers prepare at the clinic and place into your knee.

Sources

1. The 2015 Cochrane review of 27 trials (1,767 participants) found intra-articular corticosteroid better than sham for knee OA pain (SMD -0.40, 95% CI -0.58 to -0.22; NNTB 8), but the benefit decayed with time: moderate at 1-2 weeks, small at 13 weeks, and no evidence of any effect at 26 weeks. All outcomes were graded LOW quality.

   Jüni P, et al. — Intra-articular corticosteroid for knee osteoarthritis.. Cochrane Database Syst Rev, 2015. DOI: 10.1002/14651858.CD005328.pub3.

2. A meta-analysis of 14 placebo cohorts (1,076 patients) found intra-articular NORMAL SALINE alone produced statistically and clinically meaningful improvement in VAS pain and WOMAC scores lasting up to 6 months - meaning a large share of the improvement people attribute to an injection is not attributable to the drug in the syringe.

   Saltzman BM, et al. — The Therapeutic Effect of Intra-articular Normal Saline Injections for Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies.. Am J Sports Med, 2017. DOI: 10.1177/0363546516680607.

3. The RESTORE randomized trial (288 participants, leukocyte-poor PRP, 3 weekly injections) found no significant difference from saline placebo at 12 months in knee pain (-2.1 vs -1.8 points; difference -0.4, 95% CI -0.9 to 0.2) or in medial tibial cartilage volume (-1.4% vs -1.2%), with 29 of 31 secondary outcomes also showing no between-group difference.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

4. A 2024 network meta-analysis of 48 studies (9,338 knees) at minimum 6-month follow-up ranked PRP first for pain and function (SUCRA 91.5), then BMAC (76.5) and hyaluronic acid (53.1), with corticosteroid (15.2) barely above placebo (13.7) at that time point.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

5. A 2022 BMJ systematic review and meta-analysis of 169 trials (21,163 participants) found viscosupplementation produced only a small pain reduction versus placebo (SMD -0.08, 95% CI -0.15 to -0.02; about -2.0 mm on a 100 mm VAS), below the minimal clinically important difference, and trial sequential analysis indicated conclusive evidence of clinical equivalence with placebo since 2009.

   Pereira TV, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.. BMJ, 2022. DOI: 10.1136/bmj-2022-069722.

6. A qualitative study interviewing 38 patients and 19 primary care clinicians found patients valued injections as an alternative to treatments they found undesirable, but reported wide variation in access, in onset and in how long the effect lasted; clinicians described an overarching theme of 'caution and competence', including uncertainty about the evidence and guidelines and the possibility of placebo.

   Moore AJ, et al. — Intra-articular corticosteroid injections for osteoarthritis: A qualitative study of patients' and clinicians' experiences.. PLoS One, 2024. DOI: 10.1371/journal.pone.0311668.

7. The RUbICOn mixed-methods HTA study, commissioned specifically to address uncertainty about recurrent injections, combined a UK primary-care cohort (2005-2020) linked to hospital data with a safety analysis, patient and clinician interviews, and a three-round Delphi to set research priorities - the current formal acknowledgement that the long-term risks and benefits of repeat injections remain unresolved.

   Whitehouse MR, et al. — RecUrrent Intra-articular Corticosteroid injections in Osteoarthritis: the RUbICOn mixed-methods study.. Health Technol Assess, 2025. DOI: 10.3310/LFAJ9337.